Boehringer antes up on a €627.5M deal for rights to Au­ti­fony’s schiz­o­phre­nia drugs

Boehringer In­gel­heim has lined up an op­tion on the schiz­o­phre­nia drugs un­der de­vel­op­ment at GSK spin­out Au­ti­fony, in­clud­ing the lead ther­a­py AUT00206.

Start­ing with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER